TY - JOUR
T1 - Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma
AU - Hutterer, Georg C.
AU - Karakiewicz, Pierre I.
AU - Zippe, Craig
AU - Lüdecke, Gerson
AU - Boman, Hans
AU - Sanchez-Carbayo, Marta
AU - Casella, Roberto
AU - Mian, Christine
AU - Friedrich, Martin G.
AU - Eissa, Sanaa
AU - Akaza, Hideyuki
AU - Serretta, Vincenzo
AU - Hedelin, Hans
AU - Rupesh, Raina
AU - Miyanaga, Naoto
AU - Sagalowsky, Arthur I
AU - Perrotte, Paul
AU - Lotan, Yair
AU - Marberger, Michael J.
AU - Shariat, Shahrokh F.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/3
Y1 - 2008/3
N2 - OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test (≥10 units/mL) and 80 (3.0%) had non-TCC recurrence. Most of these, i.e. 60 (75%), were stage ≥T2. The sensitivity and specificity of urinary cytology were, respectively, 20.0% and 94.8%, vs 77.5% and 81.8% for NMP22 of ≥10 units/mL. The predictive accuracy of urinary cytology was 57.5%, vs 87.1% for NMP22 ≥ 10 units/mL. A combined model that included dichotomized NMP22 and urinary cytology was 85.3% accurate. CONCLUSION: The ability of a NMP22 level of ≥10 units/mL to predict non-TCC recurrence was better than that of urinary cytology, suggesting that NMP22 might have a role in the surveillance of patients at risk of non-TCC recurrence.
AB - OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test (≥10 units/mL) and 80 (3.0%) had non-TCC recurrence. Most of these, i.e. 60 (75%), were stage ≥T2. The sensitivity and specificity of urinary cytology were, respectively, 20.0% and 94.8%, vs 77.5% and 81.8% for NMP22 of ≥10 units/mL. The predictive accuracy of urinary cytology was 57.5%, vs 87.1% for NMP22 ≥ 10 units/mL. A combined model that included dichotomized NMP22 and urinary cytology was 85.3% accurate. CONCLUSION: The ability of a NMP22 level of ≥10 units/mL to predict non-TCC recurrence was better than that of urinary cytology, suggesting that NMP22 might have a role in the surveillance of patients at risk of non-TCC recurrence.
KW - Bladder cancer
KW - Disease recurrence
KW - NMP22
KW - Prediction
KW - Squamous cell carcinoma
KW - Transitional cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=38849101720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38849101720&partnerID=8YFLogxK
U2 - 10.1111/j.1464-410X.2007.07352.x
DO - 10.1111/j.1464-410X.2007.07352.x
M3 - Article
C2 - 18257856
AN - SCOPUS:38849101720
SN - 1464-4096
VL - 101
SP - 561
EP - 565
JO - BJU international
JF - BJU international
IS - 5
ER -